De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.01816 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Nadia Harbeck und 27 weiteren Autor:innen. Beteiligte Einrichtung: West German Study Group, Moenchengladbach, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective of the hormone receptor status. Trastuzumab-emtansine (T-DM1), antibody-drug conjugate, is highly effective in HER2+ EBC; however, no survival data are available for de-escalated antibody-drug conjugate–based neoadjuvant therapy without conventional chemotherapy. PATIENTS AND METHODS In the WSG-ADAPT-TP (ClinicalTrials.gov identifier: NCT01779206 ) phase II trial, 375 centrally reviewed patients with hormone receptor-positive (HR+)/HER2+ EBC (clinical stage I-III) were randomly assigned to 12 weeks of T-DM1 with or without endocrine therapy (ET) or trastuzumab + ET once every 3 weeks (ratio 1:1:1). Adjuvant chemotherapy (ACT) omission was allowed in patients with pathologic complete response (pCR). In this study, we report the secondary survival end points and biomarker analysis. Patients who received at least one dose of study treatment were analyzed. Survival was analyzed using the Kaplan-Meier method, two-sided log-rank statistics, and Cox regression models stratified for nodal and menopausal status. P values < .05 were considered statistically significant. RESULTS T-DM1, T-DM1 + ET, and trastuzumab + ET induced similar 5-year invasive disease-free survival (iDFS; 88.9%, 85.3%, 84.6%; P log-rank = .608) and overall survival rates (97.2%, 96.4%, 96.3%; P log-rank = .534). Patients with pCR versus non-pCR had improved 5-year iDFS rates (92.7% v 82.7%; hazard ratio, 0.40 [95% CI, 0.18 to 0.85]). Among the 117 patients with pCR, 41 did not receive ACT; 5-year iDFS rates were similar in those with (93.0% [95% CI, 84.0 to 97.0]) and without ACT (92.1% [95% CI, 77.5 to 97.4]; P log-rank = .848). Translational research revealed that tumors with PIK3CA wild type, high immune marker expression, and luminal-A tumors (by PAM50) had an excellent prognosis with de-escalated anti-HER2 therapy. CONCLUSION The WSG-ADAPT-TP trial demonstrated that pCR after 12 weeks of chemotherapy-free de-escalated neoadjuvant therapy was associated with excellent survival in HR+/HER2+ EBC without further ACT. Despite higher pCR rates for T-DM1 ± ET versus trastuzumab + ET, all trial arms had similar outcomes because of mandatory standard chemotherapy after non-pCR. WSG-ADAPT-TP demonstrated that such de-escalation trials in HER2+ EBC are feasible and safe for patients. Patient selection on the basis of biomarkers or molecular subtypes may increase the efficacy of systemic chemotherapy-free HER2-targeted approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- West German Study Group, Moenchengladbach, Germany.
- Department of Gynecology and Obstetrics and CCCMunich, Breast Center, LMU University Hospital, Munich, Germany.
- Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany.
- Institute of Pathology, Medical School Hannover, Hannover, Germany.
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
- Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Nadia Harbeck, Matthias Christgen, Sherko Kümmel, Claudia Schumacher, Jochem Potenberg, Bahriye Aktas, Helmut Forstbauer, Eva-Maria Grischke, Wolfram Malter, Katarzyna Jóźwiak, Michael Hauptmann, Monika Graeser, Oleg Gluz
Zitieren
APA
Harbeck, N., Nitz, U. A., Christgen, M., Kümmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Forstbauer, H., Grischke, E. M., Scheffen, I., Malter, W., von Schumann, R., Just, M., Zu Eulenburg, C., Biehl, C., Kolberg-Liedtke, C., Deurloo, R., …, & WSG-ADAPT investigators (2023). De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01816
Vancouver
Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, et al. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01816
BibTeX
@article{Harbeck2023,
author = {Harbeck, Nadia and Nitz, Ulrike A and Christgen, Matthias and Kümmel, Sherko and Braun, Michael and Schumacher, Claudia and Potenberg, Jochem and Tio, Joke and Aktas, Bahriye and Forstbauer, Helmut and Grischke, Eva-Maria and Scheffen, Iris and Malter, Wolfram and von Schumann, Raquel and Just, Marianne and Zu Eulenburg, Christine and Biehl, Claudia and Kolberg-Liedtke, Cornelia and Deurloo, Regula and de Haas, Sanne and Jóźwiak, Katarzyna and Hauptmann, Michael and Kates, Ronald and Graeser, Monika and Wuerstlein, Rachel and Kreipe, Hans H and Gluz, Oleg and WSG-ADAPT investigators, WSG-ADAPT investigators},
title = {De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.01816}
}
EUVIMED